GSK £61m buy-out rescues Cellzome platform from venture wasteland
This article was originally published in Scrip
Executive Summary
The £61 million purchase of Cellzome gives GlaxoSmithKline a cutting-edge platform in proteomics. However, the real story behind the acquisition is one of a small company running out of money and venture investors running out of time to get any return on their investment.